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were utilized to simulate a Cost-Effectiveness Acceptability Curve of each clinical 
area and type of intervention i.e. screening or vaccination program. Results: 
The cost-effectiveness function of prevention programs yield an ICER < € 30.000/
QALY in 80% of realizations. Vaccines are the most efficient interventions, since 
they exhibit an ICER lower than treatments of the same clinical in more than 90% 
of simulations ConClusions: Prevention programs typically require immedi-
ate investments yielding future health benefits. To acknowledge this peculiarity 
means to adopt not only a short (Vaccinations against influenza , chicken pox 
, measles), but also a medium (vaccination against zoster, genital warts , and 
tetanus) and long time horizon (screening of cancers and hepatitis) when assess-
ing the efficiency of healthcare programs. Failure to reach the threshold of 5 % 
of spending on prevention required by Italian national healthcare planning, is 
therefore to be understood as a form of rationing, rather than rationalization of 
healthcare resources.
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objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when 
wholesalers were also authorized, pharmaceuticals under this status could only 
be imported by the Turkish Pharmacists’ Association (TPA The aim of this study 
is to understand the trends in L subgroups (Antineoplastic and immunomodu-
lating agents) of ATC classification system unlicensed medicine consumption 
between 2011 and 2013 when the TPA was the only authorized supplier. Methods: 
Consumption data of L sub-group in the top 100 imported unlicensed medicines 
with the highest sales share in total expenses of imported off-label use was taken 
from the TMMDA computer database. L01, L02, L03 and L04 were taken as subgroups. 
Descriptive analysis was conducted. Results: The analysis showed that the L01 
had the highest percentage of active ingredients among L subgroups with 67% share 
in all L group medicines. The percentage of L01 rose from 67% to 76% between 2011 
and 2013. The consumption of L01 rose from 61 million TL to 230 million TL in the 
same period. L01 has the highest percentage of unit sales as well. ConClusions: 
The cost of imported medicines used in off-label use is increasing every year in 
Turkey. Some cost-containment measures (especially for L01-antineoplastic agents) 
should be taken to reduce the cost without risking patients’ access to innovative 
medicines.
PHP136
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objeCtives: Medication errors are unintentional errors in how medicines are pre-
scribed, dispensed, administered, or monitored while controlled by a healthcare 
professional, patient, or consumer. Leendertse et al (2008) reported that 5.6% of 
acute hospital admissions are medication-related, of which 46.5% were poten-
tially preventable. This study estimated the costs related to medication errors 
that lead to avoidable hospitalizations in Belgium. Methods: Based on the inci-
dences from Leendertse et al (2008), the number of hospital admissions due to 
avoidable medication errors in Belgium was determined. The total avoidable costs 
attributable to medication errors was estimated, by multiplying the number of 
avoidable hospitalizations with the average cost of a hospital stay, calculated 
using the online official database of the Technical Cell (data from 2011). Costs 
were inflated to 2014. Results: The estimated average cost of a hospital stay in 
Belgium was € 4,886. Based on 2.6%, the incidence rate of total hospital admissions 
attributable to medication errors, 42,797 hospital admissions that could have been 
avoided due to medication errors were estimated. Avoiding these hospitaliza-
tions would produce potential savings of € 209Mn per year. ConClusions: This 
study shows that the economic and health burden of preventable medication 
errors is high. As such, a synergic approach is warranted nationally and across 
national borders. This should entail communication and involvement from all 
different stakeholders (medical doctors, pharmacists, hospitals, national and 
international pharmacovigilance organizations) in the provision and delivery 
of care.
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objeCtives: Prior to February 2013, price management within Astellas Pharma 
Europe Ltd. was done manually using an Excel database. The system was labour 
intensive, slow to update, and prone to error. We developed an innovative web-
based pricing information management system to address the shortcomings of the 
previous system. Methods: A secure web-based system for submitting, review-
ing and approving pricing requests was developed for use by 21 affiliates in 40 
countries in Europe, Middle East and Africa. The aims of the new system were 
to: (i) reduce time/effort to approve price change requests; (ii) reduce the risk of 
using incorrect/unapproved prices; (iii) improve the visibility of pricing data to 
affiliates; (iv) improve approval process compliance. The system was designed 
to: track all pricing applications and approval status; update approved pricing 
information automatically; provide fixed and customisable reports of pricing 
increase in the number of new chemical entities (NCEs) previously launched (1994-
2002) - had higher increase in mean age at death, controlling for the effects of 
macroeconomic trends and overall changes in the healthcare system. Results: 
The diseases for which more drugs were registered during the period 1994-2002 
had larger increases in mean age at death during 2002-2010. The increase in mean 
age at death for “high-innovation diseases” (mean number of NCE 1994-2002 = 
12.9) was 3.1 years, while 1.7 years for “low-innovation diseases” (mean number 
of NCE 1994-2002 = 3.9). Furthermore, our estimates indicate that about 1/3 of the 
total increase in longevity (i.e. 0.8 years) was due to NCE 1994-2002. Thus, phar-
maceutical innovation increased mean age at death by 1.2 months per year. There 
were 106,242 deaths in Portugal in 2010. Hence the number of life-years gained in 
2010 due to drugs registered during the period 1994-2002 was 84,994 (= 0.80 years * 
106,242 deaths). ConClusions: These findings demonstrate that pharmaceutical 
innovation brought significant health gains in Portugal in the past decade. Access to 
innovation is therefore crucial if society desires to mantain the positive momentum 
of longevity increase.
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objeCtives: Antibiotic use outside hospital in Belgium is known to be one of 
the highest in Europe. This has aside an impact on resistance also an important 
economic burden. The aim of this study was to evaluate the potential savings that 
could be realized in case prescription behavior in Belgium would be similar to the 
Netherlands, a country known for its strict antibiotic use. Methods: Current 
spending levels for antibiotics were determined in Belgium and the Netherlands. 
Volume and value sales were determined per country (average number of pills sold 
per capita) based on IMS Health Belgian National Retail Database available to IMS 
Health in both countries via the IMS MIDAS platform (2013 data). The potential 
country-level prescription cost in Belgium was estimated by multiplying aver-
age number of pills/person in the Netherlands, with the cost/pill in Belgium and 
extrapolating the result to the total population in Belgium, assuming that prescrib-
ing levels in Belgium were equal to those in the Netherlands and using Belgian 
prices. Also reasons for antibiotic use were checked in the IMS Longitudinal 
Patient Database. Results: In Belgium the number of pills per capita was sig-
nificantly higher compared to the Netherlands (12.66 vs. 5.93 pills/person). With 
a 30% smaller population than the Netherlands, spending in Belgium is 3 times 
higher. The estimated savings for the Belgian payer applying the usage (pill/per-
son) of the Netherlands and current cost/pill in Belgium were € 71.5 Mn. Reasons 
for antibiotics prescription in Belgium were mainly upper airway infections and 
bronchitis. ConClusions: By comparing Belgium’s prescription patterns to the 
Netherlands, we estimated important potential savings due to antibiotics mis-use/
over-use. The additional health and cost implications of antibiotics resistance 
were not taken into account. These savings could then be reinvested in covering 
innovative drugs.
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objeCtives: The aim of this study is to analyze the impact of multimorbidity on 
ambulatory pharmaceutical cost and hospital cost. We use Clinical Risk Groups 
(CRG) for determining the multimorbidity. CRG is a classification system for risk 
adjustment which assigns each individual to risk groups based on chronic condi-
tion. Methods: In a cross-sectional study we extracted the data of cost and co-
morbidity using CRGs from a data base of 156.811 people register with the health 
district of Denia, in eastern Spain, during 2013. Two OLS models were constructed for 
natural logarithm of the dependent variable of pharmaceutical and the other being 
hospital cost per patient respectively. Both models we take as independent variables 
the nine main health status of CRG. Results: The ambulatory pharmaceutical 
cost represents 27.00% of the total expenditure. The CRG with the highest related 
ambulatory costs was CRG 7 (Dominant chronic disease in 3 or more organ systems 
(38.77%)). The highest hospital costs were found to be in the groups of higher sever-
ity levels (8.Dominant and metastatic malignances and 9.Catastropihc conditions), 
being 80.86% and 85.23% respectively. The statistical analysis showed a higher level 
of significance in the ambulatory pharmaceutical cost model: R squared of 58.8% 
versus the 12.8% in the hospital model. ConClusions: There is wide variability 
in the percentage of outpatient expenditure between the different status levels of 
the CRG. The explanatory capacity of the CRG is much higher when it is outpatient 
cost because patients suffering with chronic conditions are regular users of the 
Primary Care than of Hospital Care.
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objeCtives: To review evidence on cost-effectiveness of screening and vaccina-
tion programs currently funded in Italy, in order to develop a tool to appraise the 
efficiency of healthcare expenditure on prevention. Methods: Cost-utility studies 
carried out in Italy between 1995 and 2014 where gathered though PubMed search 
engine. The following inclusion criteria were applied to the records retrieved: (i) 
Cost-Utility analysis; (ii) Italian setting; (iii) National Health Service Perspective; 
(iv) lifetime horizon; (v) intervention belonging to one of these clinical area: viral 
hepatitis, cancers, metabolic and cardiovascular diseases; infectious or respiratory 
disease. Prevention programs have been ordered in league tables. Mean and stand-
ard deviation of incremental values and ICERs reported in the selected studies 
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government and private health insurers. Results: The total revenue and costs of 
PHI companies were 2.3 billion TL and 1.7 billion TL and per capita revenue and cost 
of private health insurance companies were 822 TL and 631 TL in 2013, respectively. 
The gross profit of all PHI companies was 0.6 billion or 26%. The SSI’s revenue and 
cost for health insurance were 53 billion and 49.9 billion TL, per capita revenue and 
cost of health insurance were 691 TL and 650 TL in 2013, respectively. The gross profit 
of SSI health insurance was 4.1 billion and 5%. ConClusions: The SSI has become 
the monopsonic payer in the Turkish health system with mandatory health insur-
ance premium collection from all Turkish citizen. The SSI determines its revenues 
and costs. Based on this power, the SSI has 4.1 billion gross revenue in total. This 
shows the success of SSI’s management while covering the whole population for a 
very comprehensive health care package. However, the SSI’s per capita revenue is 
lower and its cost is higher than private sector averages.
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objeCtives: To assess current status of HTA implementation in Central-Eastern 
European (CEE) countries and to identify long-term objectives considering country 
specific aspects and regional commonalities. Methods: An HTA implementation 
survey was designed to identify, present and discuss HTA roadmaps in CEE coun-
tries. The survey was conducted among participants at the Fifth Adriatic Congress 
of Pharmacoeconomics and Outcomes Research (Sibenik) and at the Pilot ISPOR HTA 
Training for CEE countries in June 2015 (Zagreb). Opinion of respondents on cur-
rent and preferred future status of HTA implementation in their own country were 
described related to capacity building, HTA financing, process and organisational 
structure for HTA, standardization of HTA methodology, use of local data, scope of 
mandatory HTA, and decision criteria. Results: 41 participants (78% public sector 
employees) from 11 CEE countries filled in the survey. 75% of respondents would 
prefer postgraduate training for HTA capacity building, however, only 15% reported 
a currently implemented program and 33% reported no regular HTA trainings in 
their countries. Participants would increase public funding on HTA research (6% 
current vs. 65% preferred) and on critical appraisal of HTA submissions (15% cur-
rent vs. 64% preferred). 73% of participants would prefer establishment of public 
HTA agency with academic support, however only 10% reported the existence of 
such agency. 92% of respondents would mandate the use of local data with need for 
assessing the transferability of international evidence (vs. 34% currently). 86% would 
prefer development of patient registries and access to data in payers’ databases (vs. 
11% currently). ConClusions: Our results must be viewed as an initial step in a 
multi-stakeholder dialogue on HTA implementation. Each CEE country should 
develop their own HTA roadmap, as such roadmaps are not fully transferable with-
out taking into account country size, GDP per capita, major social values, public 
health priorities and fragmentation of health care financing.
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objeCtives: The Italian Medicine Agency (AIFA) has recently introduced con-
ditional reimbursement schemes to promote access to oncology therapies, and 
reduce the risk of funding treatments with lower effectiveness than observed 
in clinical trials. These schemes are designed to be terminated after few years 
once treatment value is reassessed based on available real world data. Payment 
by Results (PbR) is frequently applied; manufacturers would be asked to pay back 
the treatment costs for patients receiving the new therapy if progression occurs 
before a pre-specified threshold. Methods: A simulation tool was built to assess 
the impact of the implementing PbR scheme and quantify the resulting increase 
in clinical value of a new treatment. Progression Free Survival (PFS) curves have 
been simulated using parametric distributions and hazard ratios to generate vari-
ous scenarios that may be observed in clinical trials. Patients receiving the new 
treatment and experiencing a recurrence before the PbR threshold were censored 
within the survival curves. PbR was also investigated considering Bevacizumab 
(Bev) in cervical cancer (CC). Results: The improvement in mPFS resulting of PbR 
was significant and meaningful in every scenario generated. The magnitude of the 
benefit depended mostly of the shape of parametric distribution. When applied 
to Bev in CC, a 3-month PbR scheme resulted in an improvement of Bev mPFS 
from 8.3 to 10.0 months (leading to a 4.1 months median incremental benefit over 
chemotherapy). ConClusions: Based on this simulation study, and the underlying 
assumptions, the patient access scheme proposed by AIFA would, in most scenarios, 
be associated with an increase in median incremental benefit for the patients, fewer 
costs for the payers and therefore better value for money.
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objeCtives: In recent years there has been an increasing strain on healthcare 
budgets. As a result, policymakers have adapted the framework for evaluating new 
medicines so manufacturers need to demonstrate additional benefit and value for 
money to achieve reimbursement. One of the key policy tools available are man-
aged entry agreements. In the UK these are assessed as patient access schemes 
(PAS) which have been successfully used to obtain cost effectiveness since 2007. 
information; collect pricing and reimbursement rules from each country; validate 
pricing and reimbursement rules monthly. The system was piloted by 3 affiliates 
(4 users). Results: The web-based system was introduced in March 2013, and 
has 246 users. The number of pricing applications/year increased from 124 (2012) 
with the Excel-based system to 455 (2013) and 312 (2014) with the web-based sys-
tem. The mean time for price approval/rejection decreased from approximately 
40 days (old system) to 6.5 days (new system). The mean time to respond to a 
pricing request decreased from 4 days (old system) to 0 days (i.e. information is 
available on new system). The estimated time needed to create monthly updates 
decreased from 1–2 days to 1–2 minutes (for simple reports). Further, the system 
enabled analyses to be performed internally, which would previously have been 
outsourced. ConClusions: The e-pricing system has improved the efficiency, 
reliability, compliance, transparency and ease of access to multinational drug 
pricing and approval information.
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objeCtives: Biosimilar discount expectations are often quoted at 20-30% of the 
originator’s price, but this benchmark was hugely underrated during recent tender 
bids in Norway. Orion Oyj astonished many when it decreased the price of its inf-
liximab biosimilar by 72%, a 69% discount vs. the originator. In our study, we aim 
to evaluate the risk of similar discounting levels occurring in the EU5 markets for 
IV biosimilars in the hospital setting. Methods: We evaluated IV biosimilar and 
originator biologic pricing, access and procurement policies across the EU5 markets 
to develop hypotheses on extreme biosimilar discounting risk levels. Results: All 
EU5 markets require biosimilars to launch at a discounted net price to attain reim-
bursement, and net pricing is negotiated at several levels. Regions and hospital pur-
chasing groups are anticipated to attain the greatest discounts or rebates, which will 
likely be greatest during exclusive or single-biosimilar source tenders that can shape 
biosimilar share. Payers using direct purchasing at the individual hospital level and 
those which leverage several non-price focused biosimilar adoption policies are 
expected to attain lower biosimilar discounts, due to reduced bargaining power or 
a lower dependence on cost savings to shape biosimilar uptake. ConClusions: We 
hypothesise that Spain, the UK and regions in Italy with exclusive tenders are at the 
greatest relative risk of repeating similar extreme discounting behaviours. France, 
Germany and regions in Italy not holding exclusive tenders are anticipated to realise 
lower biosimilar discounts. Furthermore, the lowest discounts are anticipated in 
non-hospital IV settings in Germany, where non-price focused biosimilar policies 
are expected to encourage adoption in treatment naïve patients, and exclusive 
rebate contracts with the originator will slow down switching of stable patients 
and biosimilar net price reductions.
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objeCtives: Activity-based financing (T2A) reforms in France in 2004 led to the 
creation of a list of high-cost drugs reimbursed outside the hospital budget, the 
“liste-en-sus”. In 2013, this spending was over 2.8 billion Euro, with 7.5% growth. 
Consequently, the French government has adopted multiple measures to control 
spending on “liste-en-sus” drugs. The most common measure taken is removal 
from the list. Patients and manufacturers have claimed that without such financ-
ing, removed drugs would not be prescribed, effectively denying access to certain 
products with marketing authorisation. We investigated the validity of this claim 
and the impact on healthcare spending of “liste-en-sus” removal. Methods: Using 
government ATIH data on “liste-en-sus” products and IMS MIDAS prescribing data, 
we identified 64 brands (48 molecules) removed from the list between 2007 and 2015. 
We then measured prescribing before and after removal and categorized the removal 
decisions. Results: Reasons for removal from the “liste-en-sus” can be categorised 
as follows: Price cut following launch of a generic or a biosimilar: 36 (20 molecules) 
Marketing authorization withdrawn: 3 Prescribing shift to retail setting: 4 Insufficient 
clinical value: 21 (of which 8 are announced for 2015/16). IMS MIDAS data analysis of 
the 13 products removed for insufficient clinical value between 2006-2013 shows that 
prescribing of half of these products was maintained or even increased, suggesting 
that removal did not deprive patients of authorized medicines. Sales of the remaining 
products fell after removal, as suitable alternatives were available for patients. For 
drug manufacturers, removal typically reduces sales; either through price discounts 
to achieve hospital reimbursement levels, or a fall in prescribing. ConClusions: 
The French “liste-en-sus” is meant to offer temporary funding for innovation, yet the 
number of removals is low. While removal has no negative consequences for patients, 
the real savings from such measures is limited and unlikely to reduce drug spending.
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objeCtives: The Health Transformation Program commenced in2002 by Ministry 
of Health(MoH) in Turkey. Today, Turkey has a well established health system 
mostly dominated by government as healthcare provider and payer. Social Security 
Institution(SSI) is the only government payer covering 99% of the Turkish population. 
There are private health insurance(PHI) companies covering only 3% of the popula-
tion. The aim of the analysis is to compared the profitability of health insurance 
in Turkey. Methods: The most updated data of revenue and cost of PHI data was 
obtained from Turkish Private Insurance Association for years 2009-2013. The official 
revenue and cost of government health insurance data was obtained from SSI for the 
same years. Descriptive analysis were conducted with the revenue and cost data of 
